Recommended Topic Related To:

Marplan

"Dec. 31, 2012 -- Depression is common among older people who go on to develop Alzheimer's disease, leading to widespread speculation that it may be one possible cause for age-related dementias.

Now, a new study suggests that rather th"...

Marplan

Marplan

Marplan Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Marplan (isocarboxazid) is used to treat symptoms of depression that may include anxiety, panic, or phobias. This medication is usually given after other antidepressants have been tried without successful treatment of symptoms. It is a monoamine oxidase inhibitor (MAOI). Common side effects include dizziness, drowsiness, tiredness, weakness, problems sleeping, constipation, and dry mouth. You may have suicidal thoughts when you first start taking an antidepressant, especially if you are younger than 24 years old. Tell your doctor if this occurs.

Starting dose of Marplan is one tablet (10 mg) twice daily. If tolerated, dosage may be increased by increments of 10 mg every 2 to 4 days to achieve a dosage of four tablets daily (40 mg) by the end of the first week of treatment. Dosage can then be increased to a maximum recommended dosage of 60 mg/day. Many other medicines can cause serious or life-threatening medical problems if taken together with Marplan. Do not take Marplan before telling your doctor about all prescription and over-the-counter medications and supplements you use. Marplan should be used only when prescribed during pregnancy. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Marplan (isocarboxazid) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Patient Information in Detail?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Marplan in Detail - Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any new or worsening symptoms such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.

Stop using isocarboxazid and call your doctor at once if you have any of these serious side effects:

  • sudden and severe headache, rapid heartbeat, stiffness in your neck, nausea, vomiting, cold sweat, sweating, vision problems, sensitivity to light;
  • chest pain, fast or slow heart rate;
  • swelling, rapid weight gain;
  • jaundice (yellowing of the skin or eyes); or
  • feeling light-headed, fainting.

Less serious side effects may include:

  • dizziness, headache;
  • tremors or shaking;
  • constipation, nausea; or
  • dry mouth.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Marplan (Isocarboxazid) »

What is Patient Information Overview?

A concise overview of the drug for the patient or caregiver from First DataBank.

Marplan Overview - Patient Information: Side Effects

SIDE EFFECTS: See also Warning section.

Dizziness, drowsiness, tiredness, weakness, problems sleeping, constipation, and dry mouth may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: fainting, mental/mood changes (e.g., agitation, confusion), muscle stiffness/twitching, changes in sexual ability/interest, shaking (tremor), shivering, swollen ankles/legs, unusual weight gain, vision changes (e.g., double/blurred vision).

Tell your doctor immediately if any of these highly unlikely but very serious side effects occur: severe stomach/abdominal pain, persistent nausea/vomiting, seizures, dark urine, yellowing eyes/skin.

This drug may rarely cause an attack of extremely high blood pressure (hypertensive crisis), which may be fatal. Many drug and food interactions can increase this risk (See also Drug Interaction section.) Stop taking isocarboxazid and seek immediate medical attention if any of these serious side effects occur: frequent/severe headache, fast/slow/irregular/pounding heartbeat, chest pain, neck stiffness/soreness, severe nausea/vomiting, sweating/clammy skin (sometimes with fever), widened pupils, sudden sensitivity to light (photophobia).

A serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction include: rash, itching/swelling (especially of the face/tongue/throat), dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Marplan (Isocarboxazid)»

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Marplan FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Adverse Findings Observed in Short-Term, Placebo-Controlled Trials

Systematically collected data are available from only 86 patients exposed to Marplan (isocarboxazid) , of whom only 52 received doses of ≥ 50 mg/day, including only 11 who were dosed at ≥ 60 mg/day. Because of the limited experience with systematically monitored patients receiving Marplan (isocarboxazid) at the higher end of the currently recommended dose range of up to 60 mg/day, caution is indicated in patients for whom a dose of 40 mg/day is exceeded (see WARNINGS).

The table that follows enumerates the incidence, rounded to the nearest percent, of treatment emergent adverse events that occurred among 86 depressed patients who received Marplan (isocarboxazid) at doses ranging from 20 to 80 mg/day in placebo-controlled trials of 6 weeks in duration. Events included are those occurring in 1% or more of patients treated with Marplan (isocarboxazid) and for which the incidence in patients treated with Marplan (isocarboxazid) was greater than the incidence in placebo-treated patients.

The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied.

The commonly observed adverse event that occurred in Marplan (isocarboxazid) patients with an incidence of 5% or greater and at least twice the incidence in placebo patients were nausea, dry mouth, and dizziness (see Table). In three clinical trials for which the data were pooled, 4 of 85 (5%) patients who received placebo, 10 of 86 (12%) who received < 50 mg of Marplan (isocarboxazid) per day, and 1 of 52 (2%) who received ≥ 50 mg of Marplan (isocarboxazid) per day prematurely discontinued treatment. The most common reasons for discontinuation were dizziness, orthostatic hypotension, syncope, and dry mouth.

Treatment-Emergent Adverse Events Incidence in Placebo-Controlled Clinical Trials with Marplan (isocarboxazid) Doses of 40 to 80 mg/day1

BODY SYSTEM/
ADVERSE EVENT
PLACEBO
(N=85)
MARPLAN < 50 mg
(N=86)
MARPLAN (isocarboxazid) ≥ 50 mg
(N=52)2
MISCELLANEOUS
Drowsy 0 4% 0%
Anxiety 1 2% 0%
Chills 0% 2% 0%
Forgetful 1% 2% 2%
Hyperactive 0% 2% 0%
Lethargy 0% 2% 2%
Sedation 1% 2% 0%
Syncope 0% 2% 0%
INTEGUMENTARY
Sweating 0% 2% 2%
MUSCULOSKELETAL
Heavy feeling 0% 2% 0%
CARDIOVASCULAR
Orthostatic hypotension 1% 4% 4%
Palpitations 1% 2% 0%
GASTROINTESTINAL
Dry mouth 4% 9% 6%
Constipation 6% 7% 4%
Nausea 2% 6% 4%
Diarrhea 1% 2% 0%
UROGENITAL
Impotence 0% 2% 0%
Urinary frequency 1% 2% 0%
Urinary hesitancy 0% 1% 4%
CENTRAL NERVOUS SYSTEM
Headache 13% 15% 6%
Insomnia 4% 4% 6%
Sleep disturbance 0% 5% 2%
Tremor 0% 4% 4%
Myoclonic jerks 0% 2% 0%
Paresthesia 1% 2% 0%
SPECIAL SENSES
Dizziness 14% 29% 15%
1Events reported by at least 1% of patients treated with Marplan (isocarboxazid) are presented, except for those that had an incidence on placebo greater than or equal to that on Marplan (isocarboxazid) .
2All patients also received Marplan (isocarboxazid) at doses < 50 mg.

Other Events Observed During the Postmarketing Evaluation of Marplan (isocarboxazid)

Isolated cases of akathisia, ataxia, black tongue, coma, dysuria, euphoria, hematologic changes, incontinence, neuritis, photosensitivity, sexual disturbances, spider telangiectases, and urinary retention have been reported. These side effects sometimes necessitate discontinuation of therapy. In rare instances, hallucinations have been reported with high dosages, but they have disappeared upon reduction of dosage or discontinuation of therapy. Toxic amblyopia was reported in one psychiatric patient who had received isocarboxazid for about a year; no causal relationship to isocarboxazid was established. Impaired water excretion compatible with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) has been reported.

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class

Marplan (isocarboxazid) is not a controlled substance.

Physical and Psychological Dependence

Marplan (isocarboxazid) has not been systematically studied in animals or humans for its potential for abuse, tolerance, or physical dependence. There have been reports of drug dependency in patients using doses of Marplan (isocarboxazid) significantly in excess of the therapeutic range. Some of these patients had a history of previous substance abuse. The following withdrawal symptoms have been reported: restlessness, anxiety, depression, confusion, hallucinations, headache, weakness, and diarrhea. Consequently, physicians should carefully evaluate Marplan (isocarboxazid) patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse (eg, development of tolerance, incrementations of dose, drug-seeking behavior).

Read the entire FDA prescribing information for Marplan (Isocarboxazid) »

A A A

Marplan - User Reviews

Marplan User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Marplan sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Emotional Wellness

Get tips on therapy and treatment.

advertisement
advertisement
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations